OBJECTIVES: @entity3483 ( @entity3483 ) has a poor prognosis. Most @entity1 are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic chemotherapy (IPHC) using @entity900 in a study with a pharmacokinetic evaluation. METHODS: @entity1 with @entity3483 , performance status of 0-1, possibility of good lung expansion and Cr<1.2mg/dL were treated with IPHC. The circuit was filled with 2000mL of normal saline containing @entity900 at a dose of 80mg/m(2). Under video-assisted thoracoscopic surgery, the thoracic cavity was filled and perfused at a speed of approximately 1L/min at a temperature of 43  C for 1h. Perfusion solution and plasma samples were periodically collected, and concentrations of protein-unbound (free) @entity902 , which was the active derivative of @entity900 , and total @entity902 were determined by flameless atomic absorption spectrometry. RESULTS: Twenty @entity1 with @entity3483 (8 lung cancers, 7 @entity2615 , and 5 others) were enrolled in this study. Rate of free @entity902 concentration relative to total @entity902 concentration in perfusion solution after 1hr IPHC at 43  C was 61.1  12.9%. Area under curve (AUC) of free @entity902 in the pleural space was calculated to be 26.3 g/mLxh, resulting in complete control of @entity1143 for 3 months after IHPC in all cases (95% confidence interval: 83-100%). While, absorption rate of total @entity902 from the pleural space was 33.8  17.0% (27.4  13.6mg/m(2)), and the maximum concentration of total @entity902 in serum was low, 0.66  0.31 g/mL, resulting in controllable side effects; grade 1 @entity8 : 6 @entity1 , grade 1 emesis: 7 @entity1 . CONCLUSIONS: IPHC with @entity900 showed favorable pharmacokinetic profiles for an optional treatment to control @entity3483 .

Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using @entity900 in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesotheliomas'] @entity3483 :: ('MESH:D016066', 'Disease') :: ['Malignant pleural effusion', 'MPE', 'malignant pleural effusion'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity3483 :: (MESH:D016066,Disease) :: ['malignant pleural effusion']
